Statistical Analysis Plan
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Dosing Time Matters
bioRxiv preprint doi: https://doi.org/10.1101/570119; this version posted March 21, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. Dosing Time Matters 1 2,3 4,5,6 1* Marc D. Ruben , David F. Smith , Garret A. FitzGerald , and John B. Hogenesch 1 Division of Human Genetics, Center for Chronobiology, Department of Pediatrics, Cincinnati Children's Hospital Medical Center, 240 Albert Sabin Way, Cincinnati, OH, 45229 2 Divisions of Pediatric Otolaryngology and Pulmonary and Sleep Medicine, Cincinnati Children’s Hospital Medical Center, 3333 Burnet Ave, Cincinnati, OH 45229 3 Department of Otolaryngology-Head and Neck Surgery, University of Cincinnati School of Medicine, 231 Albert Sabin Way, Cincinnati, OH, 45267 4 Department of Systems Pharmacology and Translational Therapeutics, at the University of Pennsylvania Perelman School of Medicine, Philadelphia, PA 19104 USA 5 Department of Medicine, at the University of Pennsylvania Perelman School of Medicine, Philadelphia, PA 19104 USA 6 Institute for Translational Medicine and Therapeutics (ITMAT), at the University of Pennsylvania Perelman School of Medicine, Philadelphia, PA 19104 USA *Corresponding Author. Email: [email protected] Abstract Trainees in medicine are taught to diagnose and administer treatment as needed; time-of-day is rarely considered. Yet accumulating evidence shows that ~half of human genes and physiologic functions follow daily rhythms. Circadian medicine aims to incorporate knowledge of these rhythms to enhance diagnosis and treatment. -
Spirometry Protocol and Software Training Handout
SPIROMETRY PROTOCOL AND SOFTWARE TRAINING HANDOUT Spirometry Protocol Key Points in Performing Spirometry ▪ Always demonstrate the maneuver ▪ Prompt the participant to BLAST out the air ▪ Continue by having the participant PUSH out the air ▪ Continue until the balloon bursts or at least six seconds Getting ready to do Spirometry Subjects will be instructed to not use any bronchodilator medicines for at least 4 hours prior to the appointment (in the case of salmeterol [Serevent] or Fomoterol (foradil)or Tritoprium (Spiriva) avoid for 12 hours prior to the test). Bronchodilator medicines include: Short acting bronchodilators Albuterol (ventolin, proventil, airet, volmax tablet) Levalbuterol (xopenex) Metaproterenol (alupent) Pirbuterol (maxair) Terbutaline (brethaire, brethine, bricanyl) Isoetharine (bronkosol) Ipratropium (atrovent) Ipratropium and albuterol combination (Combivent) Isoproteranol (isuprel) Primatine 1 CHW Educational Protocols – Spirometry Protocol and Software Training Handout Bitolterol (tornalate) Long acting bronchodilator Salmeterol (serevent) Fomoterol (foradil) Tritoprium (Spiriva) Bronchodilators should be avoided because they can affect the spirometry results. If the patient is having symptoms from asthma and needs to use the medicine, ask that the medicine be used 4 hours before the visit, so that the next dose is due during the visit. Patients can then do the spirometry and then the patient can take the medicine after the test is completed. When scheduling the follow-up spirometry visit, if at all possible, try to make the visit at the same time as the initial baseline visit. 1. Preparing the Computer 1. Check to see if the time and date on the lower right hand corner is current. If the date and time is NOT, the spirometer will NOT sync with the computer or the Easy One software. -
Separation of Β-Receptor Blockers and Analogs by Capillary Liquid Chromatography
ORIGINAL ARTICLES College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, China Separation of b-receptor blockers and analogs by Capillary Liquid Chromatography (CLC) and Pressurized Capillary Electrochromatography (pCEC) using a vancomycin chiral stationary phase column Zhongyi Chen, Su Zeng, Tongwei Yao Received September 15, 2006, accepted October 28, 2006 Tongwei Jao, Department of Pharmaceutical Analysis and Drug Metabolism, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, 310031, China [email protected] Pharmazie 62: 585–592 (2007) doi: 10.1691/ph.2007.8.6194 Enantiomeric separation of chiral pharmaceuticals was carried out by means of in capillary liquid chroma- tography (CLC) and pressurized capillary electrochromatography (pCEC) using a vancomycin chiral sta- tionary phase (CSP). A 100 mm I.D. fused-silica capillary was packed with 5 mm diameter silica particles modified with vancomycin. Enantiomeric resolution of fifteen b-receptor blockers and analogs was stu- died by polar organic CLC mode and reversed-phase pCEC mode using mobile phases containing methanol-isopropanol-acetic acid-triethylamine and TEAA buffer-methanol, respectively. Several factors affecting chiral separation were investigated in both CLC and pCEC mode. Good enantiomeric resolution was achieved by CLC mode for propranolol, celiprolol, esmolol, bisoprolol, atenolol, metoprolol and car- teolol using methanol-isopropanol-acetic acid-triethylamine (70 : 30 : 0.05 : 0.05, v/v/v/v) as mobile phase and for clenbuterol, bambuterol, terbutaline, and salbutamol using methanol-isopropanol-acetic acid- triethylamine (50 : 50 : 0.05 : 005 or 50 : 50: 0.025 : 0.05, v/v/v/v) as mobile phase. The baseline was achieved by pCEC mode for the separation of esmolol, bisoprolol, atenolol, metoprolol, carteolol in the mobile phase containing MeOH-0.05%TEAA (pH 7.0) (90 : 10, v/v) (–10 kV), and that of propranolol and celiprolol in the mobile phase containing MeOH-0.025%TEAA (pH 7.0) (90 : 10, v/v)(–10 kV). -
18 December 2020 – to Date)
(18 December 2020 – to date) MEDICINES AND RELATED SUBSTANCES ACT 101 OF 1965 (Gazette No. 1171, Notice No. 1002 dated 7 July 1965. Commencement date: 1 April 1966 [Proc. No. 94, Gazette No. 1413] SCHEDULES Government Notice 935 in Government Gazette 31387 dated 5 September 2008. Commencement date: 5 September 2008. As amended by: Government Notice R1230 in Government Gazette 32838 dated 31 December 2009. Commencement date: 31 December 2009. Government Notice R227 in Government Gazette 35149 dated 15 March 2012. Commencement date: 15 March 2012. Government Notice R674 in Government Gazette 36827 dated 13 September 2013. Commencement date: 13 September 2013. Government Notice R690 in Government Gazette 36850 dated 20 September 2013. Commencement date: 20 September 2013. Government Notice R104 in Government Gazette 37318 dated 11 February 2014. Commencement date: 11 February 2014. Government Notice R352 in Government Gazette 37622 dated 8 May 2014. Commencement date: 8 May 2014. Government Notice R234 in Government Gazette 38586 dated 20 March 2015. Commencement date: 20 March 2015. Government Notice 254 in Government Gazette 39815 dated 15 March 2016. Commencement date: 15 March 2016. Government Notice 620 in Government Gazette 40041 dated 3 June 2016. Commencement date: 3 June 2016. Prepared by: Page 2 of 199 Government Notice 748 in Government Gazette 41009 dated 28 July 2017. Commencement date: 28 July 2017. Government Notice 1261 in Government Gazette 41256 dated 17 November 2017. Commencement date: 17 November 2017. Government Notice R1098 in Government Gazette 41971 dated 12 October 2018. Commencement date: 12 October 2018. Government Notice R1262 in Government Gazette 42052 dated 23 November 2018. -
Chronic Obstructive Lung Disease
Chronic Obstructive Lung Disease Amita Vasoya, DO FACOI FCCP FAASM Christiana Care Pulmonary Associates Clinical Assistant Professor of Medicine Sidney Kimmel Medical College of Thomas Jefferson University Rowan University School of Osteopathic Medicine ACOI Board Review 2019 Disclosures No Disclosures Obstructive Lung Diseases COPD Chronic ◦ Chronic Bronchitis Bronchitis Emphysema ◦ Emphysema Asthma Other ◦ Bronchiectasis Asthma ◦ Bronchiolitis ◦ Cystic Fibrosis ◦ Alpha 1 anti-trypsin deficiency Inter-relationship: Inflammation and Bronchial Hyperreactivity ATS GOLD CHEST 2002; 121: 121S-126S COPD THIRD leading cause of death worldwide It is the only leading cause of death whose prevalence is increasing! http://www.who.int/mediacentre/factsheets COPD Risk Factors Cigarette smoking Occupational exposures ◦ Silica, formaldehyde, toluene, nickel, cadmium, cotton, dust, etc Air pollution Biomass fuel Hyperresponsive airway Asthma Genetic factors Pathogenesis of COPD ATS Pulmonary Board Review 2015 Inflammatory Mediators: COPD ATS Pulmonary Board Review 2015 INFLAMMATION Small Airway Disease Parenchyma destruction Airway inflammation Loss of alveolar attachments Airway remodeling Decreased elastic recoil AIRFLOW LIMITATION ATS Pulmonary Board Review 2015 COPD Phenotypes Non-exacerbator Exacerbator with emphysema Exacerbator with chronic bronchitis Frequent exacerbator Alpha 1 Antitrypsin deficiency ACOS BCOS www.eclipse-copd.com, Lange P. Int J COPD 2016. 11: 3-12 Hurst JR. NEJM 2010. 363: 1128-38 Morphologic Types of -
Clenbuterol Human Effects the Effect of Clenbuterol in Humans Is Researched Through Examining the History and Regulations of the Drug
Clenbuterol Human Effects The effect of clenbuterol in humans is researched through examining the history and regulations of the drug. Specifically, Alberto Contador’s case is considered. Tag Words: Clenbuterol; drugs; Beta-2 Agonist; Effects; Thermogenic; Fat; Harmful; Authors: Jessie Yeh, Horace Lau, Danielle Lovisone with Julie M. Fagan, Ph.D. Summary (written by Danielle Lovisone) As a sympathomimetic and Beta-2 agonist, clenbuterol have several deleterious effects on the human body. The drug acts as a thermogenic stimulant, increasing lean muscle mass and respiratory efficiency while reducing fat. Cases on clenbuterol, including animal tests and human occurrences, support these unnatural and potentially harmful effects. With this, athletes and body builders have recently increased their use of the drug. Particularly, Alberto Contador has recently been targeted for having traces of clenbuterol in a urine drug test. Contador claims, instead of doping, this trace amount was unknowingly received from ingesting beef in Spain during the 2010 Tour de France. Although clenbuterol is banned in most areas of the world, this explanation seems plausible because the drug is poorly regulated by organizations such as the FDA. To examine Contador’s case further, our group compiled research on clenbuterol to ultimately hypothesize that Contador received this trace amount from contaminated beef. Our findings were submitted to the World Anti-Doping Agency as part of our Service Project. Video Link Class project 2010 fall: www.youtube.com/watch?v=ZTeJiBvbLhA The Issue: Clenbuterol The Effects of Clenbuterol on the Human Body By Jessie Yeh What is Clenbuterol? Clenbuterol is a chemical compound closely resembling the structure of an amine. -
Validation of New Analytical Methodology for Determining Fenoterolhydrobromide by HPLC: Application in Pharmaceutical Products
Artigo Original/Original Article Validation of new analytical methodology for determining fenoterolhydrobromide by HPLC: application in pharmaceutical products Validação de uma nova metodologia analítica para determinação de bromidrato de fenoterol por CLAE: aplicações em produtos farmacêuticos RIALA6/1475 *Helena Miyoco YANO1, Fernanda Fernandes FARIAS1, Marcelo Beiriz DEL BIANCO1, Pedro Lopez GARCIA2 *Endereço para correspondência: 1Núcleo de Ensaios Físicos e Químicos em Medicamentos, Centro de Medicamentos, Cosméticos e Saneantes, Instituto Adolfo Lutz, Av. Doutor Arnaldo, 355, CEP: 01246-902, São Paulo, SP, Brasil. E-mail: [email protected] 2Departamento de Farmácia, Faculdade de Ciências Farmacêuticas, Universidade de São Paulo, São Paulo, SP, Brasil. Recebido: 31.10.2011- Aceito para publicação: 20.04.2012 RESUMO Bromidrato de fenoterol é um agente agonista adrenérgico β2-seletivo utilizado para tratamento de asma e doenças pulmonares crônicas obstrutivas. A metodologia analítica por cromatografia líquida de alta eficiência (CLAE) foi desenvolvida e validada para a determinação quantitativa de bromidrato de fenoterol. A condição analítica empregada incluiu coluna em fase reversa C18 (150 mm × 3,9 mm d.i., 5 µm) Thermo®, fase móvel composta de mistura de acetonitrila e água (30:70, v/v) com 0,1% de trietilamina e pH ajustado para 5,0 com ácido fórmico, vazão de 1,0 mL.min-1 e detecção em UV a 276 nm. A faixa de linearidade foi de 0,025 a 0,15 mg.mL-1; a curva analítica mostrou coeficiente de correlação > 0,999. O limite de detecção (LD) foi de 0,003 mg.mL-1 e o limite de quantificação de 0,012 mg.mL-1. -
Supplementary Information
Supplementary Information Network-based Drug Repurposing for Novel Coronavirus 2019-nCoV Yadi Zhou1,#, Yuan Hou1,#, Jiayu Shen1, Yin Huang1, William Martin1, Feixiong Cheng1-3,* 1Genomic Medicine Institute, Lerner Research Institute, Cleveland Clinic, Cleveland, OH 44195, USA 2Department of Molecular Medicine, Cleveland Clinic Lerner College of Medicine, Case Western Reserve University, Cleveland, OH 44195, USA 3Case Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, OH 44106, USA #Equal contribution *Correspondence to: Feixiong Cheng, PhD Lerner Research Institute Cleveland Clinic Tel: +1-216-444-7654; Fax: +1-216-636-0009 Email: [email protected] Supplementary Table S1. Genome information of 15 coronaviruses used for phylogenetic analyses. Supplementary Table S2. Protein sequence identities across 5 protein regions in 15 coronaviruses. Supplementary Table S3. HCoV-associated host proteins with references. Supplementary Table S4. Repurposable drugs predicted by network-based approaches. Supplementary Table S5. Network proximity results for 2,938 drugs against pan-human coronavirus (CoV) and individual CoVs. Supplementary Table S6. Network-predicted drug combinations for all the drug pairs from the top 16 high-confidence repurposable drugs. 1 Supplementary Table S1. Genome information of 15 coronaviruses used for phylogenetic analyses. GenBank ID Coronavirus Identity % Host Location discovered MN908947 2019-nCoV[Wuhan-Hu-1] 100 Human China MN938384 2019-nCoV[HKU-SZ-002a] 99.99 Human China MN975262 -
Ep 2560611 B1
(19) TZZ Z___T (11) EP 2 560 611 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.: of the grant of the patent: A61K 9/00 (2006.01) 03.01.2018 Bulletin 2018/01 (86) International application number: (21) Application number: 11719211.2 PCT/EP2011/056227 (22) Date of filing: 19.04.2011 (87) International publication number: WO 2011/131663 (27.10.2011 Gazette 2011/43) (54) "PROCESS FOR PROVIDING PARTICLES WITH REDUCED ELECTROSTATIC CHARGES" VERFAHREN ZUR BEREITSTELLUNG VON PARTIKELN MIT REDUZIERTEN ELEKTROSTATISCHEN LADUNGEN PROCÉDÉ DE PRÉPARATION DE PARTICULES AYANT DES CHARGES ÉLECTROSTATIQUES RÉDUITES (84) Designated Contracting States: • GUCHARDI ET AL: "Influence of fine lactose and AL AT BE BG CH CY CZ DE DK EE ES FI FR GB magnesium stearate on low dose dry powder GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO inhaler formulations", INTERNATIONAL PL PT RO RS SE SI SK SM TR JOURNAL OF PHARMACEUTICS, ELSEVIER BV, NL LNKD- DOI:10.1016/J.IJPHARM.2007.06.041, (30) Priority: 21.04.2010 EP 10160565 vol. 348, no. 1-2, 19 December 2007 (2007-12-19), pages 10-17, XP022393884, ISSN: 0378-5173 (43) Date of publication of application: • ELAJNAF A ET AL: "Electrostatic 27.02.2013 Bulletin 2013/09 characterisation of inhaled powders: Effect of contact surface and relative humidity", (73) Proprietor: Chiesi Farmaceutici S.p.A. EUROPEAN JOURNAL OF PHARMACEUTICAL 43100 Parma (IT) SCIENCES, ELSEVIER, AMSTERDAM, NL LNKD- DOI:10.1016/J.EJPS.2006.07.006, vol. 29, no. 5, 1 (72) Inventors: December 2006 (2006-12-01), pages 375-384, • COCCONI, Daniela XP025137181, ISSN: 0928-0987 [retrieved on I-43100 Parma (IT) 2006-12-01] • MUSA, Rossella • CHAN ET AL: "Dry powder aerosol drug I-43100 Parma (IT) delivery-Opportunities for colloid and surface scientists", COLLOIDS AND SURFACES. -
Prediction of Premature Termination Codon Suppressing Compounds for Treatment of Duchenne Muscular Dystrophy Using Machine Learning
Prediction of Premature Termination Codon Suppressing Compounds for Treatment of Duchenne Muscular Dystrophy using Machine Learning Kate Wang et al. Supplemental Table S1. Drugs selected by Pharmacophore-based, ML-based and DL- based search in the FDA-approved drugs database Pharmacophore WEKA TF 1-Palmitoyl-2-oleoyl-sn-glycero-3- 5-O-phosphono-alpha-D- (phospho-rac-(1-glycerol)) ribofuranosyl diphosphate Acarbose Amikacin Acetylcarnitine Acetarsol Arbutamine Acetylcholine Adenosine Aldehydo-N-Acetyl-D- Benserazide Acyclovir Glucosamine Bisoprolol Adefovir dipivoxil Alendronic acid Brivudine Alfentanil Alginic acid Cefamandole Alitretinoin alpha-Arbutin Cefdinir Azithromycin Amikacin Cefixime Balsalazide Amiloride Cefonicid Bethanechol Arbutin Ceforanide Bicalutamide Ascorbic acid calcium salt Cefotetan Calcium glubionate Auranofin Ceftibuten Cangrelor Azacitidine Ceftolozane Capecitabine Benserazide Cerivastatin Carbamoylcholine Besifloxacin Chlortetracycline Carisoprodol beta-L-fructofuranose Cilastatin Chlorobutanol Bictegravir Citicoline Cidofovir Bismuth subgallate Cladribine Clodronic acid Bleomycin Clarithromycin Colistimethate Bortezomib Clindamycin Cyclandelate Bromotheophylline Clofarabine Dexpanthenol Calcium threonate Cromoglicic acid Edoxudine Capecitabine Demeclocycline Elbasvir Capreomycin Diaminopropanol tetraacetic acid Erdosteine Carbidopa Diazolidinylurea Ethchlorvynol Carbocisteine Dibekacin Ethinamate Carboplatin Dinoprostone Famotidine Cefotetan Dipyridamole Fidaxomicin Chlormerodrin Doripenem Flavin adenine dinucleotide -
Title 16. Crimes and Offenses Chapter 13. Controlled Substances Article 1
TITLE 16. CRIMES AND OFFENSES CHAPTER 13. CONTROLLED SUBSTANCES ARTICLE 1. GENERAL PROVISIONS § 16-13-1. Drug related objects (a) As used in this Code section, the term: (1) "Controlled substance" shall have the same meaning as defined in Article 2 of this chapter, relating to controlled substances. For the purposes of this Code section, the term "controlled substance" shall include marijuana as defined by paragraph (16) of Code Section 16-13-21. (2) "Dangerous drug" shall have the same meaning as defined in Article 3 of this chapter, relating to dangerous drugs. (3) "Drug related object" means any machine, instrument, tool, equipment, contrivance, or device which an average person would reasonably conclude is intended to be used for one or more of the following purposes: (A) To introduce into the human body any dangerous drug or controlled substance under circumstances in violation of the laws of this state; (B) To enhance the effect on the human body of any dangerous drug or controlled substance under circumstances in violation of the laws of this state; (C) To conceal any quantity of any dangerous drug or controlled substance under circumstances in violation of the laws of this state; or (D) To test the strength, effectiveness, or purity of any dangerous drug or controlled substance under circumstances in violation of the laws of this state. (4) "Knowingly" means having general knowledge that a machine, instrument, tool, item of equipment, contrivance, or device is a drug related object or having reasonable grounds to believe that any such object is or may, to an average person, appear to be a drug related object. -
Nystatin Ofloxacin Orciprenaline Sulfate
JP XV Ultraviolet-visible Reference Spectra 1619 Nystatin A solution prepared as follows: To 10 mg add 50.25 mL of a mixture of diluted methanol (4 in 5) and sodium hydroxide TS (200:1), dissolve by warming at not exceeding 509C,andadddilutedmethanol(4in5)tomake500 mL. Ofloxacin Asolutionin0.1mol/LhydrochloricacidTS(1in150,000) Orciprenaline Sulfate A solution in 0.01 mol/L hydrochloric acid TS (1 in 10,000) 1620 Ultraviolet-visible Reference Spectra JP XV Oxazolam A solution in ethanol (95) (1 in 100,000) Oxethazaine A solution in ethanol (95) (1 in 2500) Oxybuprocaine Hydrochloride An aqueous solution (1 in 100,000) JP XV Ultraviolet-visible Reference Spectra 1621 Oxycodone Hydrochloride Hydrate An aqueous solution (1 in 10,000) Oxymetholone A solution prepared as follows: To 5 mL of a solution in methanol (1 in 5000) add 5 mL of sodium hydroxide-methanol TS and methanol to make 50 mL. Oxytetracycline Hydrochloride Asolutionin0.1mol/LhydrochloricacidTS(1in50,000) 1622 Ultraviolet-visible Reference Spectra JP XV Oxytocin An aqueous solution (1 in 2000) Penbutolol Sulfate A solution in methanol (1 in 10,000) Pentazocine A solution in 0.01 mol/L hydrochloric acid TS (1 in 10,000) JP XV Ultraviolet-visible Reference Spectra 1623 Peplomycin Sulfate Asolutionpreparedasfollows:To4mgadd5mL of copper (II) sulfate TS, and dissolve in water to make 100 mL. Perphenazine 1 Asolutionin0.1mol/LhydrochloricacidTS(1in200,000) Perphenazine 2 A solution obtained by adding 10 mL of water to 10 mL of the solution for Perphenazine 1 1624 Ultraviolet-visible